Streetbeat News

THOXF

Bioporto AS

http://www.bioporto.com/

CEO

Peter Moerch Eriksen

Industry

Research and Development in Biotechnology

Open

0.31

Mkt cap

124M

Volume

36K

High

0.31

P/E Ratio

-14.40

52-wk high

0.43

Low

0.29

Div yield

N/A

52-wk low

0.23

BioPorto announced its interim results and business update for the third quarter and nine months of fiscal 2024, highlighting revenue growth and strategic execution.

Portfolio Pulse from

November 14, 2024 | 8:00 am

BioPorto Diagnostics is showcasing its ProNephro AKI and NGAL Test at major healthcare conferences in the U.S. to promote their diagnostic biomarkers for Acute Kidney Injury (AKI).

Portfolio Pulse from

November 08, 2024 | 4:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.